Recent data have shown the presence of immunological alterations in adult patients suffering from obsessive-compulsive disorder (OCD). The objective of this study was to examine the possible effects of 12 months of treatment with different serotonergic drugs, such as clomipramine and selective serotonin reuptake inhibitors (SSRIs) on peripheral immunological cells of 18 OCD patients. Both the absolute number and percent of CD4+, CD8+, CD3+, CD19+ and CD56+ cells were measured in peripheral blood before and after treatment by means of a Facstar Flow Sorter apparatus. At baseline, all patients showed a significant increase of CD8+ and decrease of CD4+ lymphocytes when compared with a similar group of healthy control subjects; after the treatment, CD8+ and CD4+ cells, respectively, decreased and increased significantly, and the CD4+/CD8+ ratio increased, when compared with baseline values, in parallel with the clinical improvement. These data suggest that the alterations of immune cells reported in patients with OCD at baseline may be reverted by treatment with SRIs and should be considered a state-dependent marker, perhaps related to a condition of stress.
Afoke AO Eeg-Olofsson O Hed J Kjellman NI Lindblom B Ludvigsson J (1993) Seasonal variation and sex differences of circulating macrophages, immunoglobulins and lymphocytes in healthy school children.Scand J Immunol37: 209–215.
2.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, fourth ed.Washington, DC: American Psychiatric Press.
3.
Åsberg M Thoren P Bertilsson L (1981) Clomipramine treatment of obsessive disorder: biochemical and clinical aspects.Psychopharmacol Bull18: 13–21.
4.
Barber Y Toren P Achiron A Noy S Wolmer L Weizman R (1996) T cell subsets in obsessive-compulsive disorder.Neuropsychobiology34: 63–66.
5.
Bastani B Arora RC Meltzer HY (1991) Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients.Biol Psychiatry30: 131–139.
6.
Bauer ME Gauer GJ Luz C Silveira RO Nardi NB Von Muhlen CA (1995) Evaluation of immune parameters in depressed patients.Life Sci57: 665–674.
7.
Bennett HT Cohen S (1993) Depression and immunity: a meta-analytic review.Psychol Bull113: 472–483.
8.
Brambilla F Perna G Bellodi L Arancio C Bertani A Perini G (1997) Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders.Biol Psychiatry42: 976–981.
9.
Bronze MS Dale JB (1993) Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain.J Immunol151: 2820–2828.
10.
Carpenter LL Heninger GR McDougle CJ Tyrka AR Epperson CN Price LH (2002) Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania.Psychiatry Res112: 257–262.
11.
Chu L Tian S Chen H Zhou Z (2002) Study on natural killer cell subset and activity in patients with depression.Zhonghua Yi Xue Za Zhi82: 830–831.
12.
Creti R Cardona F Pataracchia M Hunolstein CV Cundari G Romano A (2004) Characterisation of group a streptococcal (GAS) isolates from children with tic disorders.Indian J Med Res119: 174–178.
13.
Denckla MB Rapoport JL (1989) Neurological examination. In: MB Denckla JL Rapoport (eds), Obsessive-Compulsive Disorder in Children and Adolescents.Washington, DC: American Psychiatric Press, pp. 107–118.
14.
Denys D Fluitman S Kavelaars A Heijnen C Westenberg H (2004) Decreased TNF-alpha and NK activity in obsessive-compulsive disorder.Psychoneuroendocrinology29: 945–952.
15.
Denys D Fluitman S Kavelaars A Heijnen C Westenberg HG (2006) Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive-compulsive disorder.Psychoneuroendocrinology31: 355–360.
16.
Dinn WM Harris CL McGonigal KM Raynard RC (2001) Obsessive-compulsive disorder and immunocompetence.Int J Psychiatry Med31: 311–320.
17.
Dorian B Garfinkel PE (1987) Stress, immunity and illness – a review.Psychol Med17: 393–407.
18.
Eisen JL Leonard HL Swedo SE Price LH Zabriskie JB Chiang SY (2001) The use of antibody D8/17 to identify B cells in adults with obsessive-compulsive disorder.Psychiatry Res104: 221–225.
19.
Fineberg N (1996) Refining treatment approaches in obsessive-compulsive disorder.J Clin Psychopharmacol11: 13–22.
20.
First MB; Spitzer RL; Gibbon M; Williams JBW; (1997) Structured Clinical Interview for DSM-IV Axis I Disorders – Patient Edition (SCID-I/P, Version 2.0, 4/97 revision). Biometrics Research Department, New York State Psychiatric Institute.
21.
Garvey MA Perlmutter SJ Allen AJ Hamburger S Lougee L Leonard HL (1999) A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections.Biol Psychiatry45: 1564–1571.
22.
Gibofsky A Khanna A Suh E Zabriskie JB (1991) The genetics of rheumatic fever: relationship to streptococcal infection and autoimmune disease.J Rheumatol30: 1–5.
23.
Goodman WK Price LH Rasmussen SA (1986) The Yale Brown obsessive-compulsive scale I: development, use and reliability.Arch Gen Psychiatry46: 1006–1011.
24.
Greist JH Bandelow B Hollander E Marazziti D Montgomery SA Nutt DJ (2003) WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults.CNS Spectr8: 7–16.
25.
Hollander E Cartwright C Wong CM De Caria CM Del Giudice-Asch G Buchsbaum MS (1998) A dimensional approach to the autism spectrum.CNS Spectr3: 22–99.
26.
Hollander E Fay M Cohen B Campeas R Gorman JM Liebowitz MR (1988) Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.Arch Gen Psychiatry145: 1015–1023.
27.
Hollander E Kaplan A Allen A Cartwright C (2000) Pharmacotherapy for obsessive-compulsive disorder.Psychiatr Clin North Am23: 643–656.
28.
Hounie AG Pauls DL do Rosario-Campos MC Mercadante MT Diniz JB De Mathis MA (2007) Obsessive-compulsive spectrum disorders and rheumatic fever: a family study.Biol Psychiatry61: 266–272.
29.
Inoff-Germain G Rodriguez RS Torres-Alcantara S Diaz-Jimenez MJ Swedo SE Rapoport JL (2003) An immunological marker (D8/17) associated with rheumatic fever as a predictor of childhood psychiatric disorders in a community sample.J Child Psychol Psychiatry44: 782–790.
30.
Insel TR Mueller EA Alterman L Linnoila M Murphy DL (1985) Obsessive-compulsive disorder and serotonin: is there a connection?Biol Psychiatry20: 1174–1188.
31.
Irwin M (1999) Immune correlates of depression.Adv Exp Med Biol461: 1–24.
32.
Kawikova I Leckman JF Kronig H Katsovich L Bessen DE Ghebremichael M (2007) Decreased numbers of regulatory T cells suggest impaired immune tolerance in children with Tourette syndrome: a preliminary study.Biol Psychiatry61: 273–278.
33.
Khanna S Ravi V Shenoy PK Chandramuki A Channabasavanna SM (1997) Cerebrospinal fluid viral antibodies in obsessive-compulsive disorder in an Indian population.Biol Psychiatry41: 883–890.
34.
Kiecolt-Glaser JK Fisher LD Ogrocki P Stout JC Speicher CE Glaser R (1987) Marital quality, marital disruption, and immune function.Psychosom Med49: 13–34.
35.
Kim YR Park Q Yu BH (2004) Changes in lymphocyte subsets after short-term pharmacotherapy in patients with panic disorder.Psychiatry Res128: 183–190.
36.
Leckman JF Katsovich L Kawikova I Lin H Zhang H Kronig H (2005) Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome.Biol Psychiatry57: 667–673.
37.
Lee BW Yap HK Chew FT Quah TC Prabhakaran K Chan GS (1996) Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood.Cytometry26: 8–15.
38.
Maes M Meltzer HY Bosmans E (1994) Psychoimmune investigation in obsessive-compulsive disorder: assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations.Neuropsychobiology30: 57–60.
39.
Marazziti D Ambrogi F Vanacore R Magnani V Savino M Palego L (1992a) Immune cell imbalance in major depressive and panic disorder.Neuropsychobiology26: 23–26.
40.
Marazziti D Catena M Pallanti S (2006) Pharmacological treatment of obsessive-compulsive disorder.Psychiatr Ann36: 454–462.
41.
Marazziti D Hollander E Lensi P Ravagli S Cassano GB (1992b) Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder.Psychiatry Res42: 41–51.
42.
Marazziti D Masala I Rossi A Hollander E Presta S Giannaccini G (2000) Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD.Neuropsychobiology41: 171–177.
43.
Marazziti D Mungai F Vivarelli L Dell’Osso B (2004) Critical issues in the pharmacological treatment of obsessive-compulsive disorder.Clin Neuropsychiatry1: 59–64.
44.
Marazziti D Presta S Pfanner C Gemignani A Rossi A Sbrana S (1999) Immunological alterations in adult obsessive-compulsive disorder.Biol Psychiatry15: 810–814.
45.
Marazziti D Rossi A Gemignani A Giannaccini G Pfanner C Milanfranchi A Presta S Lucacchini A Cassano GB (1996) Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients.Neuropsychobiology34: 184–187.
46.
Martini E D’Hautcourt JL Lawry J O’Connor JE Sansonetti F (1990) First European Quality Control of Cellular Phenotyping by Flow Cytometry.Paris: Frison-Roche.
47.
Martino D Church AJ Defazio G Dale RC Quinn NP Robertson MM (2005) Soluble adhesion molecules in Gilles de la Tourette’s syndrome.J Neurol Sci234: 79–85.
48.
Montgomery SA (1994) Pharmacological treatment of obsessive-compulsive disorder. In: E Hollander J Zohar D Marazziti B Olivier (eds), Current Insights in Obsessive-Compulsive Disorder.Chichester: Wiley and Sons, pp. 123–137.
49.
Morer A Vinas O Lazaro L Bosch J Toro J Castro J (2005) D8/17 monoclonal antibody: an unclear neuropsychiatric marker.Behav Neurol16: 1–8.
50.
Morer A Vinas O Lazaro L Calvo R Andres S Bosch J (2006) Subtyping obsessive-compulsive disorder: clinical and immunological findings in child and adult onset.J Psychiatr Res40: 207–213.
51.
Murphy TK Benson N Zaytoun A Yang M Braylan R Ayoub E (2001) Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder.J Neuroimmunol120: 146–151.
52.
Murphy TK Goodman WK Fudge MW Williams RC Ayoub EM Dalal M (1997) B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette’s syndrome?Am J Psychiatry154: 402–407.
53.
Navalta JM Sedlock DA Park KS McFarlin BK (2007) Neither gender nor menstrual cycle phase influence exercise-induced lymphocyter apoptosis in untrained subjects.Appl Physiol Nutr Metab32: 481–486.
54.
Nie NH Hull CH Steinbrenner K Bent DH (1998) Statistical Package for the Social Science (SPSS), fourth ed.New York: McGraw-Hill.
55.
Pallanti S Hollander E Bienstock C Koran L Leckman J Marazziti D (2002) Treatment non-response in OCD: methological issues and operational definitions.Int J Neuropsychopharmacol5: 181–191.
56.
Pallanti S Quercioli L (2006) Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines.Prog Neuropsychoparmacol Biol Psychiatry30: 400–412.
57.
Perlmutter SJ Leitman SF Garvey MA Hamburger S Feldman E Leonard HL (1999) Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood.Lancet354: 1153–1158.
58.
Perna FM Schneiderman N LaPerriere A (1997) Psychological stress, exercise and immunity.Int J Sport Med18: 78–83.
59.
Piccinelli M Pini S Bellantuono C Wilkinson C (1995) Efficacy of drug treatment in obsessive-compulsive disorder.Br J Psychiatry166: 424–443.
60.
Rabkin JG Wagner G Rabkin R (1994) Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial.J Clin Psychiatry55: 433–439.
61.
Ravindran AV Griffiths J Merali Z Anisman H (1995) Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment.Psychosom Med57: 555–563.
62.
Ravindran AV Griffiths J Merali Z Anisman H (1998) Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features.Psychosom Med60: 283–289.
63.
Ravindran AV Griffiths J Merali Z Anisman H (1999) Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls.J Affect Disord52: 1–10.
64.
Sallee FR Richman H Beach K Sethuram G Nesbitt L (1996) Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette’s syndrome.J Am Acad Child Adolesc Psychiatry35: 1647–1656.
65.
Schleifer SJ Keller SE Camarino E Thornton JC Stein M (1983) Suppression of lymphocyte stimulation following bereavement.J Am Med Assoc250: 374–377.
66.
Schlesinger M Yodfat Y Rabinowitz R Bronner S Kark JD (1993) Psychosocial stress and NK cells among members of a communal settlement.Adv Exp Med Biol335: 247–254.
67.
Simpson HB Huppert JD Petkova E Foa EB Liebowitz MR (2006) Response versus treatment in obsessive-compulsive disorder.J Clin Psychiatry67: 269–276.
68.
Singer HS Hong JJ Yoon DY Williams PN (2005) Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls.Neurology65: 1701–1707.
69.
Sluzewska A Rybakowski JK Laciak M Mackiewicz A Sobieska M Wiktorowicz K (1995) Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.Ann N Y Acad Sci762: 474–476.
70.
Smith JM Shen Z Wira CR Fanger MW Shen L (2007) Effects of the menstrual cycle status and gender on human neutrophil phenotype.Am J Reprod Immunol58: 111–119.
71.
Swedo SE (2002) Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS).Mol Psychiatry7: 24–25.
72.
Swedo SE Leonard HL Garvey M Mittleman B Allen AJ Perlmutter S (1998) Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases.Am J Psychiatry155: 264–271.
73.
Swedo SE Leonard HL Kiessling LS (1994) Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood.Pediatrics93: 323–326.
74.
Swedo SE Leonard HL Mittleman BB Allen AJ Rapoport JL Dow SP (1997) Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever.Am J Psychiatry154: 110–112.
Thoren P Asberg M Cronholm B (1980) Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial.Arch Gen Psychiatry37: 1281–1289.
77.
Tolin DF Abramowitz JS Diefenbach GJ (2005) Defining response in clinical trials for obsessive-compulsive disorder: a signal detection of the Yale-Brown obsessive-compulsive scale.J Clin Psychiatry66: 1549–1557.
78.
Warren RP Margaretten NC Pace NC Foster A (1986) Immune abnormalities in patients with autism.J Autism Dev Disord16: 189–197.
79.
Weisz JL McMahon WM Moore JC Augustine NH Bohnsack JF Bale JF (2004) D8/17 and CD19 expression on lymphocytes of patients with acute rheumatic fever and Tourette’s disorder.Clin Diagn Lab Immunol11: 330–336.
80.
Weizman R Carmi M Hermesh H Shahar A Apter A Tyano S (1986) High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients.Am J Psychiatry143: 335–339.
81.
Yovel G Shakhar K Ben-Eliyahu S (2001) The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells.Gynecol Oncol81: 254–262.
82.
Zabriskie JB (1986) Rheumatic fever: a model for the pathological consequences of microbial-host mimicry.Clin Exp Rheumatol4: 65–73.
83.
Zisook S Shucter SR Irwin M Darko CF Sledge P Resovsky K (1994) Bereavement, depression and immune function.Psychiatr Res52: 1–10.
84.
Zohar J Chopra M Sasson Y Amiaz R Amital D (2000) Obsessive compulsive disorder: serotonin and beyond.World J Biol Psychiatry1: 92–100.
85.
Zohar J Insel TR (1987) Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology.Biol Psychiatry22: 667–687.
86.
Zohar J Mueller EA Insel TR Zohar-Kadouch RC Murphy DL (1987) Serotonergic responsivity in obsessive-compulsive disorder.Arch Gen Psychiatry44: 946–951.
